Management

Members of China Healthcare and its advisory team have strong marketing, international business, investing, and research experience in pharmaceutical industries in both the United States and China. Managing directors have been speakers at many international biotechnology and pharmaceutical conferences. 

China Healthcare Group

Bill Liang is CEO of China Healthcare Group and managing director China Healthcare Consulting. Dr. Liang has 12 years of biomedical research and investment experience in pharmaceutical and financial industries. Prior to joining China Healthcare, he worked as an associate analyst in Convergent Venture LLC, a biomedical venture capital firm and Wedbush Morgan Securities, an investment-banking firm in Los Angeles respectively. Dr. Liang received a Ph.D. in Molecular and Cellular Biology from the University of Massachusetts at Amherst and a M.B.A. from the University of Southern California, and had three-year postdoctoral training at the Harvard Medical School.  His China venture experiences included the successful marketing of numerous foreign branded medical products and formation of several million-dollar product co-development programs with Chinese healthcare firms. 

Peter Song is the country manager of China Healthcare Group in South Korea.  Mr. Song has 20 years of experience in pharmaceutical sales and marketing in Korea. He served various management roles in Bristol Myers Korea, MSD Korea and Eli Lilly Korea. Prior to joining CHCC, Mr. Song was a senior national sales director in Bristol Myers Korea responsible for 340% sales growth for its lead cancer and anti-infective drugs over 6 year period. He led the launch of a dozen of blockbuster drugs in Korea during his professional career. His experience and industrial resource in Korean healthcare industry add significant values to our services. Mr. Song received a Bachelor degree in Agrichemistry from Kangwon National University, Chuncheon and a MBA from Seogang University.

China Healthcare Consulting

Ken Li is managing director of China Healthcare Consulting. Ken has 15 years of marketing, international business and research experience in pharmaceutical industries in both China and the United States. Prior to joining CHCC, Ken worked as a research scientist at Wyeth, while serving as a board of director for Telstar Innovation Inc., the leading U.S. etailer for alternative medicine. His experience in the Chinese healthcare industry includes establishing a three million-dollar medical device joint venture company and taking the product under development to the late stage clinical trial. Before coming to the United States, Mr. Li served as a project manager for Sichuan Pharmaceutical Industrial Corporation in China where he managed two multi million-dollar investment projects, and supervised product promotion and public relation with leading Chinese pharmaceutical and medical product firms. Ken received a Master of Science degree in Chemistry from the City University of New York, and a M.B.A. from Babson College.

Fan Xiao is managing director of China Healthcare Consulting in China, and CEO of Beijing AODAKANG Medical-Medicine Science Co. Ltd., specializing in regulatory application of new drugs, medical devices and nutraceutical products in China. Mr. Xiao has 15-years of Chinese marketing and drug application experience. Before joining CHCC, Fan served in various leading Chinese pharmaceutical firms with  responsibilities in new drug application and new product launch and market analysis. Under his supervision, the companies won approvals for dozens of drug and nutraceutical products by the State of Drug Administration and the Ministry of Health. He has a record of exceptional results working with the regulatory agencies in China.  He was also instrumental in bringing the IPO of a domestic healthcare company to the Hong Kong stock market exchange.